Search results for: Multi-Indication Therapies
Filter search results
Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing
11 May 2018
…be achieved, when increasingly medicines are being developed that derive patient benefit across many different indications? Indication-based pricing (IBP) has been proposed as a way to tackle this issue, permitting…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
…indications? Indication-based pricing (IBP) has been proposed as a way to tackle this issue, permitting price to vary according to indication and – critically – according to value. The notion…
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
20 October 2025
…of healthcare innovations, such as cell and gene therapies. It evaluates the economic gains that the large-scale adoption of advanced therapies could provide for individuals, the NHS, and the wider…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
…always expanding, one important limitation is the difficulty in assessing medicine use according to what that medicine has been used for, where the medicine has multiple indications. This impedes our…
The value of cell and gene therapies to the UK economy
20 October 2025
…access to cell and gene therapies (CGT) in just four indications could create health benefits with a value exceeding £20 billion over 10 years, for individuals, systems and the UK…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
…the body. Despite generating a paradigm shift these therapies are faced with multiple challenges to fit the regulatory and health technology assessment frameworks used by healthcare decision-makers. Yet, with an…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
…current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future. Multi-indication pricing (MIP) is based on the idea of recognising the value…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
31 March 2015
…Institute for Health and Care Excellence (NICE). These activities are impeded if medicine use cannot be ascribed to indication. For example, multi-indication medicines were left out altogether from reports by…
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
…therapies. When these models are likely to be employed, they should be factored into BIAs to inform decision making, commercial negotiations, and implementation. Share this: Download publication Gene therapies represent…